Incyte Halts Phase III Clinical Trial for Myelofibrosis
Incyte announced the termination of Phase III LIMBER-304 trial after the results of a pre-planned interim analysis conducted by an independent data monitoring committee (IDMC) revealed that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. The recommendation to end the study was not based on safety concerns. LIMBER-304 is a randomized, double-blind study comparing the efficacy and safety of parsaclisib plus ruxolitinib (Jakafi®) versus placebo plus ruxolitinib in adult (age 18 years) patients with myelofibrosis (MF) who have not responded to ruxolitinib monothe...
